Genomic variants report solutions from Prof. Roberto Grobman 2023: How we do it? We created a series of complex interconnected algorithms together with AI technology, capable of translating the scientific data and results of these scientific publications into useful information, and over the years we have been creating a unique FullDNA database. Our Technology experts built a unique AI system that knows to compare results of genetic tests, such as sequencing and genotyping and translate them to useful & focused data for doctors into a variety of 25 different panels The gained knowledge of population characteristics, such as diseases probabilities, physical features, nutrition predisposition, Interacted with AI technology can extract comprehensive details on trends, such as longevity status of populations, medications that better work to individuals or groups, nutrition consuming habits, best sports for each individual, psychological features, etc. This technology can help countries plan the future of their investments in preventive medication for their population. Find additional info at Prof. Roberto Grobman.
Some pioneering hospitals have started to store pharmacogenomics reports and have integrated them within their clinical systems. This allows them, for example, to send an alert to the treating doctor and your pharmacist that says: ‘while we’re treating this person for X, please be aware, don’t use Y or Z because their pharmacogenetics test indicates alternatives with a potentially better outcome’. What does FullDNA DNA test for and how is it used? We test about 80 specific gene variants. These variants are only linked to exercise, nutrition and mental well-being (stress and sleep). No disease or diagnostic testing is involved — therefore people can really look at this as a way to help them improve their health and well-being.
Genomic variants report services by Prof. Roberto Grobman right now: As results are provided directly to the individual, they are not in your insurance or medical record (unless you share results with your healthcare professional). It is often less expensive than genetic testing obtained through a healthcare provider, which can make testing more accessible to people with no or limited health insurance. DNA sample collection is usually simple and noninvasive, and results are available quickly. Your anonymous data is added to a large database that can be used to further medical research. Depending on the company, the database may represent up to several million participants.
Genetic testing is on the rise: In recent years, there’s been a dramatic increase in genetic testing. It was nearly unheard of only a few decades ago. Now, you or someone you know has likely had genetic testing within the last year or two. And while healthcare providers can now order far more genetic tests for their patients than in the past, you don’t need a doctor’s order to request this. 23andMe, Ancestry.com, and a number of other testing companies are ready and willing to check your genes for variants associated with certain health conditions, as well as your family ancestry. In fact, spending on direct-to-consumer genetic testing is predicted to reach $2.5 billion within the next few years.
Only once we know it’s been peer reviewed and once we know that an individual can impact their health with easily modifiable environmental changes are we able to say ‘yes, we can bring this to people and help them make use of their DNA to improve their health’. Diagnosis and screening: There are different types of test available. For example, some can diagnose predispositions to certain diseases and/or conditions, for example looking for the BRCA gene — the breast cancer gene. This type of screening can be useful to doctors who might be having a hard time identifying a given disease – especially rare ones.
Our studies identified the relationship between Coronavirus and Genetics. We performed genetic analysis with more than 300 coronavirus patients in Brazil. We divided into 3 groups. A group of patients in the ICU in serious condition. A group with patients in the hospital but in a moderate state and a group with patients at home, with mild manifestation of the disease. We have a tool capable of predicting which individuals are at greater or lesser risk for the pandemic, and regarding vaccine risks. Read even more info at Roberto Grobman CTO.